Human Insulin NPH
ApprovedSmall molecule
Eli LillyHuman Insulin NPH is one of 215 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
8
Indications
23
Total Trials
0
Active Trials
214
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Human Insulin NPH
Eli LillyApproved
Arcoxia
NovartisPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Symbicort
AstraZenecaPreclinical
Aciphex
Akero TherapeuticsPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Spiriva
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes7 trials
Show 4 more trials
Type 1 Diabetes Mellitus2 trials
Type 2 Diabetes Mellitus2 trials
Type 2 Diabetic Patients2 trials
8 more indications
Hyperglycemia1 trial
Acute Kidney Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Human Insulin NPH. EMBL-EBI & Wellcome Sanger Institute.
- [4]